ONS-5010

· Outlook Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

8 regulatory and trial events tracked for ONS-5010, covering 2025-02-25 to 2026-08-03. Get the full timeline:

Most recent: Clinical Trial Results: A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) [Phase 3]

See pricing